Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 241

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1A
Chunk 241
---
 technologies, products or product candidates;

    ●
    developments
    concerning our collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization
    partners;

    ●
    announcements
    by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;

    ●
    developments
    or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent
    protection for our products;

    ●
    our
    ability or inability to raise additional capital and the terms on which we raise it;

    ●
    the
    recruitment or departure of key personnel;

    ●
    changes
    in the structure of healthcare payment systems;

    ●
    market
    conditions in the pharmaceutical and biotechnology sectors;

45

    ●
    actual
    or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other
    comparable companies or our industry generally;

    ●
    our
    failure or the failure of our competitors to meet analysts’ projections or guidance that we or our competitors may give to
    the market;

    ●
    fluctuations
    in the valuation of companies perceived by investors to be comparable to us;

    ●
    announcement
    and expectation of additional financing efforts;

    ●
    speculation
    in the press or investment community;

    ●
    trading
    volume of our common stock;

    ●
    sales
    of our common stock by us or our stockholders;

    ●
    the
    concentrated ownership of our common stock;

    ●
    changes
    in accounting principles;

    ●
    terrorist
    acts, acts of war or periods of widespread civil unrest;

    ●
    natural
    disasters and other calamities; and

    ●
    general
    economic, industry and market conditions.

In
addition, the stock markets in general, and the markets for pharmaceutical stocks, in particular, have experienced extreme volatility
that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm
the market price of our common stock, regardless of our operating performance.

The
future issuance of equity or of debt securities that are convertible into common stock will dilute our share capital.

We
may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements.
To the extent that additional capital is raised through the issuance of shares or